AstraZeneca, GB0009895292

AstraZeneca stock: FDA grants priority review to cancer drug

Published on 11/19/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock gets a faster US review for sonesitatug vedotin. The FDA action date is expected in the second quarter of 2027.

FDA review advances oncology pipeline

  • The FDA granted Priority Review to AstraZeneca's application for sonesitatug vedotin in advanced gastric and related cancers.
  • The Phase III CLARITY-Gastric01 trial reported a 42% reduction in the risk of death versus investigator's choice of therapy.
AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca said on Thursday, November 19, that the US Food and Drug Administration had accepted and granted Priority Review to its biologics license application for sonesitatug vedotin. The application covers second- and later-line treatment of adults with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma whose tumors express CLDN18.2.

The company said the FDA's action date under the Prescription Drug User Fee Act is anticipated in the second quarter of 2027. Priority Review is reserved for applications that could offer significant improvements over available treatment options; it does not represent an approval.

Phase III data support the filing

According to AstraZeneca, the application is based on the CLARITY-Gastric01 Phase III trial. In the overall second- and later-line population, sonesitatug vedotin reduced the risk of death by 42% versus investigator's choice of therapy, with an overall-survival hazard ratio of 0.58.

Sonesitatug vedotin is an investigational antibody-drug conjugate targeting CLDN18.2, a protein found in the stomach lining and a therapeutic target in gastrointestinal cancers. The candidate has also received orphan-drug designations from the FDA and the European Commission for gastric and gastroesophageal junction cancers.

Next regulatory milestone remains ahead

The regulatory decision expected in the second quarter of 2027 will be the next major milestone for the program. Until then, investors will focus on the agency's review process and on the potential commercial reach of a treatment aimed at patients whose disease has progressed after earlier lines of therapy.

AstraZeneca stock traded at 161.80 euros on Lang & Schwarz at 10:12 CET on Thursday, November 19, 2026.

UK large-cap investors also track the FTSE 100.

More news and analyses on AstraZeneca stock

AstraZeneca at a glance

  • Company: AstraZeneca PLC
  • ISIN: GB0009895292
  • Ticker: AZN
  • Lang & Schwarz quote: 161.80 euros at 10:12 CET on November 19, 2026
Disclaimer...
en | GB0009895292 | ASTRAZENECA | boerse | 70534920 | bgmi